Surabhi Dangi-Garimella, PhD

"Our analysis suggests that annual screens may not be warranted for patients who have had an initial negative scan, and future risk prediction and cost-effectiveness models could incorporate these data to improve screening guidelines," said the study's lead author.

A new study in JAMA Internal medicine has found that the concurrent use of interacting medications has increased since 2005 and that 15% of older adults are potentially at risk for a major drug-drug interaction.

Analysis of data on nearly 27,000 patients with rectal cancer found distance from site of radiation therapy, along with a few other factors, could significantly impact the possibility of the patient receiving treatment.

Based on the review of additional data submitted by Janssen, an appraisal committee from the National Institute for Health and Care Excellence (NICE) has finalized a guidance that recommends abiraterone for use in some prostate cancer patients prior to chemotherapy.

The partnership between is expected to improve access and help overcome gaps in care for consumers.

The 42nd annual meeting of the Association of Community Cancer Centers ensured that none of the oncology care providers in the audience left without realizing that healthcare has slowly been migrating to include value in care delivery and reimbursement decisions.

A new study in Australia adds to the evolving knowledge on adverse cutaneous effects of pembrolizumab and nivolumab. Could they also indicate better prognosis?

Dermatologists have conducted a research study that proves "smartphone microscopes" can improve the detection of skin cancer in remote areas and in developing nations, where specialists are not as easily accessible to patients.

FDA has granted a Priority Review designation for the breakthrough programmed death ligand-1 inhibitor atezolizumab, for the treatment of bladder cancer.

A new report published by the American Society of Clinical Oncology has drawn a mixed picture of oncology care in the United States-reduced mortality, increased survivors, and progress in treatment coupled with unsustainable costs and an unstable clinical setting.

Two inhibitors of the vascular endothelial growth factor receptor approved for the treatment of metastatic renal cell cancer do not prevent cancer recurrence when used in the adjuvant setting following surgery, according to a new study in the Lancet.

According to the American Society of Clinical Oncology, TAPUR provides patients access to drugs at no cost, and is designed to evaluate FDA-approved targeted agents for indications other than those on the drug’s label.

The proposals recommend modernizing policies across the healthcare industry, including the drug discovery and development process, promoting value-driven healthcare, increasing the consumer voice, and addressing market distortions.

Be The First is a 5-year, $50 million initiative to help deliver the nation's first tobacco-free generation.

Several healthcare organizations have sent a letter to HHS urging withdrawal of this reimbursement model.

A study conducted in Denmark identified an inverse association between controlling diabetes, through diet or oral medications, and breast density.

CMS has announced its plans to evaluate a new value-based payment model for prescription drugs covered under the Part B program. This is yet another move by the federal body to ensure quality care for Medicare enrollees.

Based on their survey results, the authors conclude that clinician communication following detection of pulmonary nodules can help bridge knowledge gaps and relieve stress.

Results of the study in JAMA underscore the importance of advance care planning.

Senators Amy Klobuchar (D-MN) and Jeanne Shaheen (D-NH) have sent a letter to the FDA urging the regulatory body to find efficient ways to distribute expensive cancer drugs.

By monitoring for mutations in the circulating tumor DNA of melanoma patients undergoing treatment, researchers at Cancer Research UK Manchester Institute are confident they can predict how patients will respond to their treatment and whether their disease would relapse.

The pharmacy benefit manager may be the "new sheriff in town" in an era of rising costs.

Just 2 days after being rejected by cost regulators in the UK, ibrutinib has been approved for the frontline treatment of patients with chronic lymphocytic leukemia in the United States.

To discuss the challenges with the implementation of value tools, the Association of Community Cancer Centers invited a panel of experts during its 42nd annual meeting on policy, value, and quality in Washington, DC.

Immunotherapy represents the "next frontier" in cancer care, according to Joseph Alvarnas, MD, of City of Hope, who is editor-in-chief of Evidence-Based Oncology.

At Cancerscape, the Association of Community Cancer Center’s 42nd annual meeting on policy, value, and quality, Kavita Patel, MD, MS, spoke about the clinical imperatives of personalized medicine and the demonstration of value to all stakeholders.

Keynote speaker Dr Julie Vose said the oncologist faces many administrative burdens in the transition to value-based care. Solving them is essential to spending more time with the patient.

Two studies presented at the recently concluded 2016 Quality Care Symposium, hosted by the American Society of Clinical Oncology, proved that hospital-based palliative care programs achieve their proposed objectives.

Imbruvica, developed by Janssen for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia who are unsuitable to receive chemo-immunotherapy, has been rejected by UK’s National Institute of Health and Care Excellence.